MedPath

Acetazolamide

Generic Name
Acetazolamide
Drug Type
Small Molecule
Chemical Formula
C4H6N4O3S2
CAS Number
59-66-5
Unique Ingredient Identifier
O3FX965V0I

Overview

One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)

Background

One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)

Indication

For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies; chronic simple (open-angle) glaucoma

Associated Conditions

  • Acute angle-closure glaucoma
  • Edema
  • Familial periodic paralysis
  • Generalized Tonic-Clonic Seizures
  • Metabolic Alkalosis
  • Open Angle Glaucoma (OAG)
  • Other and unspecified effects of high altitude
  • Cystine renal calculi
  • Drug-induced edema
  • Nonuveitic secondary glaucoma
  • Salicylate intoxication

FDA Approved Products

Acetazolamide
Manufacturer:XGen Pharmaceuticals DJB, Inc.
Route:INTRAVENOUS
Strength:500 mg in 5 mL
Approved: 2024/01/05
NDC:39822-0190
Acetazolamide
Manufacturer:Lifestar Pharma LLC
Route:ORAL
Strength:125 mg in 1 1
Approved: 2022/06/09
NDC:70756-720
Acetazolamide
Manufacturer:ANI Pharmaceuticals, Inc.
Route:ORAL
Strength:250 mg in 1 1
Approved: 2023/03/22
NDC:70954-034
Acetazolamide
Manufacturer:ANI Pharmaceuticals, Inc.
Route:ORAL
Strength:125 mg in 1 1
Approved: 2023/03/22
NDC:70954-033
Acetazolamide
Manufacturer:Aarkish Pharmaceuticals NJ Inc.
Route:ORAL
Strength:125 mg in 1 1
Approved: 2023/12/29
NDC:81005-104

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath